SCHEMBL2434541

SCHEMBL2434541

Cn1cc(-c2nc3ccc(CC(=O)O)cc3o2)c2cc(F)ccc21

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 6/20 0.60
ITGA4 P13612 6/20 0.60
PTGDR2 Q9Y5Y4 1/20 0.44
GSK3B P49841 2/20 0.44
CDK2 P24941 1/20 0.44
HPSE Q9Y251 7/20 0.42
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14627048 0.92 ITGB1 (0.58) ITGB1ITGA4PTGDR2GSK3BCDK2
SCHEMBL2433950 0.92 ITGB1 (0.59) ITGB1ITGA4PTGDR2HPSES1PR1
SCHEMBL14591801 0.89 ITGB1 (0.56) ITGB1ITGA4PTGDR2GSK3BCDK2
SCHEMBL2429639 0.88 ITGB1 (0.59) ITGB1ITGA4PTGDR2HPSEKDM4E
SCHEMBL2436328 0.87 ITGB1 (0.57) ITGB1ITGA4HPSEKDM4EALDH1A1
SCHEMBL14626706 0.84 ITGB1 (0.57) ITGB1ITGA4PTGDR2GSK3BCDK2
SCHEMBL2430981 0.82 ITGB1 (0.49) ITGB1ITGA4PTGDR2GSK3BCDK2
SCHEMBL14592396 0.82 ITGB1 (0.57) ITGB1ITGA4GSK3BCDK2HPSE
SCHEMBL14591805 0.82 ITGB1 (0.55) ITGB1ITGA4PTGDR2GSK3BCDK2
SCHEMBL2432757 0.81 ITGB1 (0.61) ITGB1ITGA4PTGDR2GSK3BCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ITGB1 5/4885ITGA4 4/4885PTGDR2 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.